Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020

Abstract

Background Lung cancer is the third most frequent tumor and the main cause of death by tumor in Spain. Although the incidence and mortality are still significantly higher in men than in women, the disparity between the sexes is decreasing. The objective of this study was to analyze the evolution of lung cancer hospitalization and in-hospital mortality rates in Spain from 2010 to 2020. Methods The reports of the Minimum Basic Data Set (MBDS) at hospital discharge were used to retrospectively analyze the data of all patients with a primary diagnosis of lung cancer, according to the International Classification of Diseases (ICD-9-CM and ICD-10-CM). Results Between 2010 and 2020, there were 315,263 hospitalizations and 70,490 deaths from lung cancer in Spain, the majority (~ 80%) in men. Overall, the rates of hospitalization and in-hospital mortality from lung cancer showed a downward trend throughout the period, although the number of new diagnoses and the absolute number of deaths in women increased. Due to the aging of the population, the degree of comorbidity in patients with lung cancer, although it remains relatively low, is also on the rise. Conclusion Lung cancer represents a substantial clinical and economic burden for patients and for the National Health System, so it is necessary to promote primary prevention campaigns, as well as to develop more effective population screening measures to detect cancers early and increase the patient survival.

Hospitalization burden associated with anus and penis neoplasm in Spain (2016-2020)

“… 24 The difference is greater than that of other hospitalization costs, such as the cost of lung cancer, which represents an estimated average cost of 5,366€ and is similar for women and men. 25 There is a greater difference from that of other cancers, such as pharyngeal cancer, whose cost was estimated to be 5,955€ in men and 5,541€ in hospitalized women; laryngeal cancer, whose estimated cost is 7,066€ in men and 7,118€ in hospitalized women; or oral cavity cancer, whose estimated cost is 7,486€ in men and 6,984€ in women hospitalized. 26 …”

Retrospective Study of Lung Cancer: Evolution in 16 Years in the Burgos Region

“…In contrast, the decrease in women is only observed in those younger than 60 years [ 15 ]. With an overall 5-year survival rate of 10–20% [ 9 ], early detection becomes crucial to improve treatment options and survival outcomes [ 19 ]. However, despite advances in understanding risk factors [ 1 ], and screening recommendations for high-risk populations [ 20 ] (adults aged 50–70 years with a smoking history of more than 20 packs per year) [ 21 ], significant gaps persist, with diagnosis at later stages of disease being the norm [ 9 , 22 , 23 ].…”

“…With figures of 2.21 million incident cases and 1.8 million deaths in 2020 [8], lung cancer is consolidated as the leading cause of cancer mortality worldwide. In the Spanish context, lung cancer is no stranger to this scenario [9]. According to the latest press release from the National Institute of Statistics, 22,727 lung cancer deaths were registered in Spain in 2022, representing 19.7% of all cancer deaths [10].…”